Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ES502
- Development stage
- Phase 1
- Lead developer
- Shanghai Essight Biotechnology
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
ES502 is a bispecific soluble T-cell receptor (TCR) fusion protein designed for the treatment of advanced solid tumors, specifically those harboring the RAS G12V mutation. Developed by Ruijin Hospital in collaboration with Essight Biopharma, the molecule consists of a soluble HLA-DP restricted TCR specific for the RAS G12V neoantigen, fused to an anti-CD3 antibody fragment and an Fc domain. This configuration allows the drug to act as a T-cell engager, redirecting T-cells to attack cancer cells presenting the RAS G12V peptide in the context of specific HLA-DP alleles. It is currently being evaluated in Phase 1 clinical trials for patients with advanced pancreatic cancer and other RAS G12V-positive solid tumors.
- Other names
- ES502 InjectionES-502 InjectionES 502 Injection
02
Targets
KRASG12V (KRAS G12V)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on ES502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ES502.